Image credit: Canva
Primary effusion lymphoma is an aggressive B-cell lymphoma caused by the Kaposi sarcoma herpesvirus (KSHV). How the disease develops is not well understood, and it does not respond well to other lymphoma treatments. A clinical trial led by Kathryn A. Lurain, M.D., M.P.H., Assistant Research Physician in the HIV and AIDS Malignancy Branch, is researching a drug for primary effusion lymphoma and multicentric Castleman disease, a similar lymphoma disorder caused by KSHV.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Anaida Widell at (240) 760-6074 or anaida.widell@nih.gov
Clinicaltrials.gov identifier: NCT05907759
NCI Protocol ID: IRB001538
Official Title: A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma and Multicentric Castleman Disease
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow, treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.